GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oncolytics Biotech ONCY · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.41

-7.21%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$39.5m

FY2016FY2025

Free cash flow

−$27.6m

FY2016FY2025

Shareholders' equity

−$5.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit−$70,000—−$288,021−$280,160−$323,088−$318,887−$347,036−$68,164−$64,871−$115,947
Research and development$18.3m$15.5m$12.7m$11.0m$9.2m$9.3m$8.0m$6.7m$6.7m$7.0m
Operating income−$39.4m−$25.0m−$24.2m−$20.4m−$18.7m−$18.2m−$14.8m−$11.9m−$11.2m−$10.9m
Net income−$39.5m−$22.7m−$19.8m−$17.7m−$18.8m−$14.0m−$32.6m−$12.2m−$11.2m−$10.8m
Diluted earnings per share-0.41-0.28-0.27-0.30-0.34-0.33-0.91-0.66-0.75-0.85

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$10.4m$14.4m$27.7m$26.7m$32.8m$24.5m$14.0m$10.6m$13.0m$10.5m
Cash and short-term investments$7.1m$12.1m$25.0m$23.0m$29.5m$22.3m$10.1m$9.8m$8.5m$10.1m
Total liabilities$15.6m$10.2m$8.0m$7.7m$7.0m$6.9m$14.1m$6.2m$7.1m$2.9m
Debt$264,821$562,463$302,315$266,580$467,947$287,349$361,832—−$1.1m$1.5m
Shareholders' equity−$5.2m$4.3m$19.7m$18.9m$25.8m$17.7m−$77,111$4.4m$5.9m$7.6m
Shares outstanding96m80m74m60m55m42m36m18m15m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$27.6m−$19.3m−$20.3m−$16.7m−$16.0m−$15.8m−$14.2m−$8.5m−$10.6m−$8.9m
Capital spending−$8,232−$170,812−$5,718−$39,308−$204,365−$20,944−$7,794−$76,805−$75,589−$16,815
Free cash flow−$27.6m−$19.4m−$20.3m−$16.7m−$16.2m−$15.8m−$14.2m−$8.6m−$10.7m−$8.9m

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Gross profit−$22,313—−$56,374————−$70,040
Operating income−$12.9m−$3.0m−$9.9m−$4.1m−$5.0m−$6.0m−$7.1m−$5.7m
Net income−$12.9m−$2.1m−$10.3m−$4.4m−$4.8m−$5.7m−$6.8m−$5.2m
Diluted earnings per share-0.11-0.02-0.11-0.04-0.04-0.07-0.09-0.06
Cash from operations−$10.0m−$8.0m−$4.0m−$3.0m−$4.0m−$19.0m−$3.0m−$4.0m
Total assets$8.2m$7.6m$10.7m$14.3m$14.1m$14.4m$17.3m$22.9m
Cash and short-term investments$5.5m$5.2m$8.8m—$11.8m$12.1m$14.0m$17.8m
Debt$166,000$193,000$198,379—$507,432$562,463$760,433$160,806
Shareholders' equity−$5.1m−$3.8m$82,063$4.4m$4.6m$4.3m$6.5m$13.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income24.5%16.7%14.8%
Net income30.5%23.1%14.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-2.1-3.2-5.0-5.5-4.1-7.1-5.2-1.8-4.7-1.5

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return36%-44%-29%24%-37%48%41%-66%162%-28%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.